Efficacy of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasia in a Large Cohort in North America. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Ngamruengphong, S., Ferri, L., Aihara, H., Draganov, P. V., Yang, D. J., Perbtani, Y. B., Jue, T. L., Munroe, C. A., Boparai, E. S., Mehta, N. A., Bhatt, A., Kumta, N. A., Othman, M. O., Mercado, M., Javaid, H., Aadam, A. A., Siegel, A., James, T. W., Grimm, I. S., DeWitt, J. M., Novikov, A., Schlachterman, A., Kowalski, T., Samarasena, J., Hashimoto, R., El Hage Chehade, N., Lee, J., Chang, K., Su, B., Ujiki, M. B., Mehta, A., Sharaiha, R. Z., Carr-Locke, D. L., Chen, A., Chen, M., Chen, Y., Khoshknab, M. P., Wang, R., Kerdsirichairat, T., Tomizawa, Y., von Renteln, D., Kumbhari, V., Khashab, M. A., Bechara, R., Karasik, M., Patel, N. J., Fukami, N., Nishimura, M., Hanada, Y., Wong Kee Song, L. M., Laszkowska, M., Wang, A. Y., Hwang, J. H., Friedland, S., Sethi, A., Kalloo, A. N. 2020


BACKGROUND & AIMS: Endoscopic submucosal dissection (ESD) is a widely accepted treatment option for superficial gastric neoplasia in Asia, but there are few data on outcomes of gastric ESD from North America. We aimed to evaluate the safety and efficacy of gastric ESD in North America.METHODS: We analyzed data from 347 patients who underwent gastric ESD at 25 centers, from 2010 through 2019. We collected data on patient demographics, lesion characteristics, procedure details and related adverse events, treatment outcomes, local recurrence, and vital status at the last follow up. For the 277 patients with available follow-up data, the median interval between initial ESD and last clinical or endoscopic evaluation was 364 days. The primary endpoint was the rate of en bloc and R0 resection. Secondary outcomes included curative resection, rates of adverse events and recurrence, and gastric cancer-related death.RESULTS: Ninety patients (26%) had low-grade adenomas or dysplasia, 82 patients (24%) had high-grade dysplasia, 139 patients (40%) had early gastric cancer, and 36 patients (10%) had neuroendocrine tumors. Proportions of en bloc and R0 resection for all lesions were 92%/82%, for early gastric cancers were 94%/75%, for adenomas and low-grade dysplasia were 93%/ 92%, for high-grade dysplasia were 89%/ 87%, and for neuroendocrine tumors were 92%/75%. Intraprocedural perforation occurred in 6.6% of patients; 82% of these were treated successfully with endoscopic therapy. Delayed bleeding occurred in 2.6% of patients. No delayed perforation or procedure-related deaths were observed. There were local recurrences in 3.9% of cases; all occurred after non-curative ESD resection. Metachronous lesions were identified in 14 patients (6.9%). One of 277 patients with clinical follow up died of metachronous gastric cancer that occurred 2.5 years after the initial ESD.CONCLUSIONS: ESD is a highly effective treatment for superficial gastric neoplasia and should be considered as a viable option for patients in North America. The risk of local recurrence is low and occurs exclusively after non-curative resection. Careful endoscopic surveillance is necessary to identify and treat metachronous lesions.

View details for DOI 10.1016/j.cgh.2020.06.023

View details for PubMedID 32565290